The CagriSema phase 2 paper and what a fixed combination buys — the long version posts 121–150

Nausea appears in the amylin-analogue literature as it does in the incretin literature, and the two are not additive in a simple way when the drugs are combined. The combination trials report tolerability separately for that reason.

That is a description of practice, not a recommendation of it.

Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.

I have kept the units in throughout, for the obvious reason.

Worth separating two things that post #135 runs together.

The practical version of CagriSema phase 2 paper is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached.

CagriSema phase 2 paper is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.

The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.

Flagging that the sources on this are thinner than the confidence in the thread suggests.

That is a fair summary of where the discussion has got to.

Checked the CagriSema phase 2 paper claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the narrower scope.

I had written a reply contradicting post #138 and deleted it. Here is what survived.

I have three months of notes on CagriSema phase 2 paper and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion from the first fortnight.

Adding the measurement that post #141 says would settle it.

The phase 3 combination programme is where the clinically interesting numbers will come from. Phase 2 established that the combination does something; the size of it in a larger population is a separate question.

Genuinely open to being wrong about this one.

Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.

Post #144 is the version of this I will quote in future. One addition.

Reframing CagriSema phase 2 paper slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.

Where I part company with post #142, and it is a narrow parting.

On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.

The rule of thumb is fine; the edge cases are where it earns its keep.

The CagriSema phase 2 paper: a fixed combination of the two components in one weekly injection. The trade-off of a fixed combination is that you cannot titrate the components independently and you cannot attribute effect to one component from a combination trial.

This settles it for me, at least until somebody posts a reason it should not.

Building on post #147 rather than restating it.

The documentation on CagriSema phase 2 paper is better than this thread and I say that as someone who has posted in the thread.

Published human data on cagrilintide alone is thinner than on the combination, which is the reverse of what most people assume from how it is discussed here.